摘要
目的比较美罗华联合CHOP方案和单用CHOP方案治疗弥漫大B细胞性淋巴瘤的疗效。方法选择日照市中医医院采用美罗华联合CHOP方案治疗的弥漫大B细胞淋巴瘤患者34例作为R—CHOP组，单用CHOP方案治疗的弥漫大B细胞淋巴瘤患者32例作为CHOP组，两组均治疗4周。观察两组治疗结束时的临床疗效以及治疗后12—24个月的远期疗效。结果R—CHOP组总有效率高于CHOP组，完全缓解率比较差异无统计学意义（P〉0．05），部分缓解率比较差异有统计学意义（P=0．032）。R—CHOP组远期疗效明显优于CHOP组，差异有统计学意义（P=0．026）。结论美罗华联合CHOP方案治疗弥漫大B细胞淋巴瘤疗效确切，远期存活率高。
Objective To compare the effects of rituximab combined with CHOP scheme and single use of CHOP scheme on patients with diffuse large B-cell lymphoma. Methods Thirty-four patients with diffuse large B-cell lymphoma in traditional Chinese medicine hospital of Rizhao treated with rituximab combined with CHOP scheme were selected as R-CHOP group, and 32 patients with diffuse large B-cell lymphoma treated with single use of CHOP scheme were selected as CHOP group, the treatment course was 4 weeks. The clinical effects were observed at the end of treatment, and the long-term effects were observed during the 12 -24 months after operation. Results The total effective rate of RCHOP group was higher than that of CHOP group. There was no significant difference in the complete response rate between the two groups. The partial remission rate was significantly higher in R-CHOP group than that in CHOP group（ P = 0. 032 ）. The long-term effect of R-CHOP group was superior to that of CHOP group, there was significant difference （P = 0. 026） between the two groups. Conclusions The effect of rituximab combined with CHOP scheme on diffuse large B-cell lymphoma is good, and the longterm survival rate is high.
出处
《中国实用医刊》
2014年第15期16-18,共3页
Chinese Journal of Practical Medicine
